EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Anti-BCMA novel therapies for multiple myeloma

Vincenzo Sammartano, Marta Franceschini, Sara Fredducci, Federico Caroni, Sara Ciofini, Paola Pacelli, Monica Bocchia, Alessandro Gozzetti

Cancer Drug Resistance · 2023 · 6 (1) · 169-181

DOI: 10.20517/cdr.2022.138 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Drug Resistance, 2023. Verfasst von Vincenzo Sammartano und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Surgery and Neuroscience, University of Siena, Azienda Ospedaliero Universitaria Senese, Siena 53100, Italy. Die Arbeit wurde bisher 31-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recent advances in multiple myeloma therapy have increased the depth of response and ultimately survivals; however, the prognosis remains poor. The BCMA antigen is highly expressed in myeloma cells, thus representing a target for novel therapies. Several agents that target BCMA through different mechanisms, including bispecific T cell engagers drug conjugated to antibody and CAR-T cells, are now available or under development. Immunotherapies targeting BCMA have shown good results in efficacy and safety in multiple myeloma patients previously treated with several lines of therapy. This review will discuss the recent development of anti-BCMA targeted treatments in myeloma, with a special focus on currently available agents.

Schlagwörter

Stichwörter der Autor:innen

BCMACARTMultiple myelomabelantamabteclistamab

Autor:innen und Institutionen

  • Department of Medicine, Surgery and Neuroscience, University of Siena, Azienda Ospedaliero Universitaria Senese, Siena 53100, Italy.
  • Authors share last co-authorship.

Zitieren

APA

Sammartano, V., Franceschini, M., Fredducci, S., Caroni, F., Ciofini, S., Pacelli, P., Bocchia, M., & Gozzetti, A. (2023). Anti-BCMA novel therapies for multiple myeloma. Cancer Drug Resistance, 6(1), 169-181. https://doi.org/10.20517/cdr.2022.138

Vancouver

Sammartano V, Franceschini M, Fredducci S, Caroni F, Ciofini S, Pacelli P, et al. Anti-BCMA novel therapies for multiple myeloma. Cancer Drug Resistance. 2023;6(1):169-181. doi:10.20517/cdr.2022.138

BibTeX
@article{Sammartano2023,
  author = {Sammartano, Vincenzo and Franceschini, Marta and Fredducci, Sara and Caroni, Federico and Ciofini, Sara and Pacelli, Paola and Bocchia, Monica and Gozzetti, Alessandro},
  title = {Anti-BCMA novel therapies for multiple myeloma},
  journal = {Cancer Drug Resistance},
  year = {2023},
  volume = {6},
  number = {1},
  pages = {169--181},
  doi = {10.20517/cdr.2022.138}
}
Kostenlos starten →